Zaradenie novej PP

Organisation: Slovenská spoločnosť infektológov

Created at: 28.03.2025

Processed at: 07.04.2026

Question

Cefiderocol is included in the List of Medicines with Officially Determined Price from 1.7.2024, it is not currently included in the list of add-on items so that it can be reimbursed separately over and above the price of the inpatient case.

We propose to include cefiderocol in the list of creditable items in the same breakdown as it appears in the list of medical procedures. More detailed reasons for the proposal were provided in feedback No 664.

To the detailed justification, which is part of feedback No.664, we attach the following: o Pharmacoeconomic analysis, which evaluates the cost-effectiveness of the drug in the conditions of the Slovak Republic o Pharmacoeconomic model o Impact of the drug on the budget of the public health insurance The above documents are separately attached.

Answer

That request has been reassessed in accordance with Chapter 8 of the Methodology for Updating Attributable Items for SK-DRG 2026, available here: https://www.cksdrg.sk/sk/dokumenty/568/Metodika%20aktualizácie%20pripočítateľných%20položiek%20pre%20SK-DRG%202026.pdf

Given that the criteria were met, the Medical Review Panel proceeded to a vote, which is recorded in the minutes available here: https://www.cksdrg.sk/sk/dokumenty/571/Zápisy%20z%20rokovaní%20medicínsko-analytickej%20pracovnej%20skupiny%20s%20hlasovaniami.pdf

The proposed PP was approved and incorporated into the CMP with a Type A reimbursement in accordance with the above methodology and by vote of the working group with the pricing resulting from the methodology as 90% of the UUC.